Journal
FEBS LETTERS
Volume 579, Issue 15, Pages 3303-3309Publisher
WILEY
DOI: 10.1016/j.febslet.2005.03.058
Keywords
cardiovascular disease; fibrinolysis; thrombolytic; plasminogen activator
Ask authors/readers for more resources
Cardiovascular disease is responsible for 17 million deaths per year but acute myocardial infarction and stroke can be treated with thrombolytics (clot busters), which are plasminogen activators. However, despite many years of study and huge investment from the pharmaceutical industry, clinical trials of new drugs have often been disappointing. Part of the problem may be our incomplete understanding of the regulation of plasminogen activation in vivo. We have developed precise in vitro methods and with the application of computer simulations, we hope to improve our understanding of plasminogen activation to facilitate improvements in thrombolytic therapy. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available